Emerging application of nanomedicine-based therapy in acute respiratory distress syndrome

被引：12

作者：

Xu, Yitianhe ^{[1
,2
,3
]}

Lv, Leyao ^{[1
,2
,3
]}

Wang, Qian ^{[1
,2
,4
]}

Yao, Qing ^{[1
,2
,4
,5
]}

Kou, Longfa ^{[1
,2
,3
,5
]}

Zhang, Hailin ^{[1
,2
,3
,6
]}

机构：

[1] Wenzhou Med Univ, Affiliated Hosp 2, Dept Pharm, Wenzhou Municipal Key Lab Pediat Pharm, Wenzhou 325027, Peoples R China

[2] Wenzhou Med Univ, Yuying Childrens Hosp, Dept Pharm, Wenzhou Municipal Key Lab Pediat Pharm, Wenzhou 325027, Peoples R China

[3] Wenzhou Med Univ, Sch Med 2, Wenzhou, Peoples R China

[4] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Peoples R China

[5] Wenzhou Med Univ, Cixi Biomed Res Inst, Zhejiang 315302, Peoples R China

[6] Wenzhou Med Univ, Affiliated Hosp 2, Dept Childrens Respirat Dis, Wenzhou 325027, Peoples R China

来源：

COLLOIDS AND SURFACES B-BIOINTERFACES | 2024年 / 237卷

关键词：

Nanomedicine; Acute lung injury; Acute respiratory distress syndrome; Drug delivery; Precision therapy; ACUTE LUNG INJURY; SOLID LIPID NANOPARTICLES; TNF-ALPHA SIRNA; DRUG-DELIVERY; PULMONARY DELIVERY; ALVEOLAR MACROPHAGES; GOLD NANOPARTICLES; PAMAM DENDRIMERS; INFLAMMATION; CHITOSAN;

D O I：

10.1016/j.colsurfb.2024.113869

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are serious lung injuries caused by various factors, leading to increased permeability of the alveolar-capillary barrier, reduced stability of the alveoli, inflammatory response, and hypoxemia. Despite several decades of research since ARDS was first formally described in 1967, reliable clinical treatment options are still lacking. Currently, supportive therapy and mechanical ventilation are prioritized, and there is no medication that can be completely effective in clinical treatment. In recent years, nanomedicine has developed rapidly and has exciting preclinical treatment capabilities. Using a drug delivery system based on nanobiotechnology, local drugs can be continuously released in lung tissue at therapeutic levels, reducing the frequency of administration and improving patient compliance. Furthermore, this novel drug delivery system can target specific sites and reduce systemic side effects. Currently, many nanomedicine treatment options for ARDS have demonstrated efficacy. This review briefly introduces the pathophysiology of ARDS, discusses various research progress on using nanomedicine to treat ARDS, and anticipates future developments in related fields.

引用

页数：18